



ORYZON GENOMICS, S.A.

Pursuant to the provisions of Article 227 of Law 6/2023 of March 17, 2022, on Securities Markets and Investment Services, and other related provisions, ORYZON GENOMICS, S.A. ("**Oryzon**" or the "**Company**") hereby announces that

OTHER RELEVANT INFORMATION

Today, the Ordinary General Shareholders' Meeting 2025 of Oryzon was held on second call, with an attendance quorum of 30.8586% of the voting rights including loyalty shares. This attendance quorum allowed all the proposed resolutions submitted to the General Shareholders Meeting (which are also listed below) to be approved by a large majority of votes.

1. Approval of the annual financial statements (balance sheet, profit and loss account, statement of changes in equity, cash flow statements and notes to the financial statements) and the management report of the Company for the year ended December 31, 2024.
2. Appropriation of income for the year ended December 31, 2024.
3. Approval of the management carried out by the Board of Directors during the fiscal year ended December 31, 2024.
4. Delegation of powers for the formalization, correction, registration, interpretation, development and execution of the resolutions adopted by the General Shareholders' Meeting and power of attorney to formalize the deposit of the annual accounts.
5. Annual report on remuneration of the Company's directors for the year ended December 31, 2024.

In accordance with the provisions of Article 525 of the Spanish Companies Act, the resolutions adopted, together with the result of the vote on each of them will be available on the Company's website.

Madrid, June 27, 2025